A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
A
April Rahrig, MD
Primary Investigator
Overview
To determine the recommended phase 2 dose (RP2D) of vorinostat in children, adolescents and young adults following allogeneic HCT.
- Eligibility:
A prospective patient for allogeneic BMT for malignant hematologic conditions - Ages 3-30
- Diagnoses include:
Acute Leukemia in remission
Chronic Myeologenous Leukemia (CML)
Myelodysplastic syndrome (MDS) - Additonal criteria must be met based on determination by Investigator and study requirements
Study participation lasts approximately 1 year.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Leukemia,Chronic Myeologenous Leukemia,CML,Myelodysplastic syndrome,MDS,
-
Age: Between 3 Years - 30 Years
-
Gender: All
Updated on
18 Apr 2024.
Study ID: 11355
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
